Extracellular vesicles: An overview of biogenesis, function, and role in breast cancer

Zha, Quan Bin; Yao, Yu; Zhao, Rongjun; Li, Xiu Juan; Tang, Jin

doi:10.1177/1010428317691182

Cited by 43 publications

(49 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes are small membrane vesicles secreted by various types of cells. 10 , 11 Exosomes play pivotal roles in inter-cellular communication via delivery of biological cargoes, including proteins, mRNAs, and miRNAs. 10 Recently, miRNAs in exosomes have been investigated as valuable biomarkers of malignancy.…”

Section: Discussionmentioning

confidence: 99%

“… 6 – 9 Exosomes are small membrane vesicles (40–120 nm) which play key roles in intercellular communication via delivery of active biological molecules. 10 , 11 Extracellular miRNAs in exosomes are relatively stable and shielded against extracellular RNase degradation. 12 – 14 Therefore, exosomal miRNAs may serve as noninvasive biomarkers for the diagnosis and prognosis of various malignancies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Liu¹,

Hu²,

Zhou³

et al. 2017

OTT

129

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (P<0.01, respectively). However, miR-125b levels in exosomes and the serum from HCC patients were inferior to that of CHB (P<0.01 and P=0.06) and LC patients (P<0.01 for all). Additionally, miR-125b levels in exosomes were associated with tumor number (P=0.02), encapsulation (P<0.01), and TNM stage (P<0.01). Kaplan–Meier analysis indicated that HCC patients with lower exosomal miR-125b levels showed reduced time to recurrence (TTR) (P<0.01) and overall survival (OS) (P<0.01). Furthermore, multivariate analysis revealed that miR-125b level in exosomes, but not in serum, was an independent predictive factor for TTR (P<0.001) and OS (P=0.011). Exosomal miR-125b levels predicted the recurrence and survival of HCC patients with an area under the ROC curve of 0.739 (83.0% sensitivity and 67.9% specificity) and 0.702 (82.5% sensitivity and 53.4% specificity). In conclusion, exosomal miR-125b could serve as a promising prognostic marker for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Liu¹,

Hu²,

Zhou³

et al. 2017

OTT

129

View full text Add to dashboard Cite

show abstract

“…They can also participate in various physiological processes including hemostasis and thrombosis, inflammation, immune interactions and angiogenesis [52,99]. Their importance is not exclusive for normal physiological processes as EVs have been implicated in the development and progression of cancer, autoimmune diseases and bacterial and viral infections [51,52,[100][101][102][103][104][105][106][107][108][109]. Therefore, there is increasing interest within the scientific community in exploring the potential application of EV-based assays as biomarkers in various diseases as well as in the adaptation of EVs as therapeutic tools in multiple clinical settings including wound healing [6,53,99,110].…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

Extracellular vesicles as modulators of wound healing

Cabral

Ryan

Griffin

et al. 2018

Advanced Drug Delivery Reviews

133

View full text Add to dashboard Cite

Impaired healing of cutaneous wounds and ulcers continues to have a major impact on the quality of life of millions of people. In recent years, the capacity for stem and progenitor cells to promote wound repair has been investigated with evidence that secreted factors are responsible for the observed therapeutic benefits. This review addresses current evidence in support of stem/progenitor cell-derived extracellular vesicles (EVs) as a regenerative therapy for acceleration of wound healing. Encouraging results for local or systemic administration of EVs have been reported in a range of clinically-relevant animal models of cutaneous wounds. Furthermore, a number of plausible mechanisms involving EV-mediated transfer of proteins and RNAs that trigger pro-repair pathways in target cells have been demonstrated experimentally. However, for successful clinical translation in the coming years, further emphasis on standardized experimental protocols, detailed methodological reporting and clear definition of EV-based therapeutic products will be required.

show abstract

“…Tang et al, 2015). Exosome-based vaccines and pre-loaded exosomes with specific antitumor miRNAs/siRNAs or cytotoxic molecules are being explored as therapeutic options for TNBC treatment (Zha, Yao, Ren, Li, & Tang, 2017). Furthermore, exosome may play a role in secretion of cytotoxic drugs out of the cells.…”

Section: Engineered Exosomesmentioning

confidence: 99%

Single peptides and combination modalities for triple negative breast cancer

Razazan

Behravan

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Unlike other types of breast cancers (BCs), no specific therapeutic targets have been established for triple negative breast cancer (TNBC). Therefore, chemotherapy and radiotherapy are the only available adjuvant therapeutic choices for TNBC. New emerging reports show that TNBC is associated with higher numbers of intratumoral tumor infiltrating lymphocytes. This is indicative of host anti-TNBC immune surveillance and suggesting that immunotherapy can be considered as a therapeutic approach for TNBC management. Recent progress in molecular mechanisms of tumor-immune system interaction and cancer vaccine development studies, fast discoveries and FDA approvals of immune checkpoint inhibitors, chimeric antigen receptor T-cells, and oncolytic virotherapy have significantly attracted attention and research directions toward the immunotherapeutic approach to TNBC. Here in this review different aspects of TNBC immunotherapies including the host immune system-tumor interactions, the tumor microenvironment, the relevant molecular targets for immunotherapy, and clinical trials in the field are discussed.

show abstract

Extracellular vesicles: An overview of biogenesis, function, and role in breast cancer

Cited by 43 publications

References 56 publications

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Extracellular vesicles as modulators of wound healing

Single peptides and combination modalities for triple negative breast cancer

Contact Info

Product

Resources

About